Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Access to life-extending drugs for the disease, which kills 10,000 a year in the UK, is poorer than in France, Spain, Germany and Italy, according to the report, sponsored by the drugs firm Astellas.
Dr Heather Payne, a consultant oncologist at University College London Hospitals NHS Foundation Trust, said: ?There are many reasons for international differences in cancer survival, but swift access to innovative treatments and the availability of best practice care are important in order to deliver the best outcomes in terms of life extension and quality of life.
She added: ?With advanced prostate cancer we are dealing with an incurable disease and every month matters for these men."
The National Institute for Health and Clinical Excellence (Nice) has been slow to recommend new prostate cancer drugs for NHS use.
Last year it said two breakthrough drugs were too expensive, including one understood to have been used in Libya to extend the life of Abdelbaset al-Megrahi, the Lockerbie bomber. It later agreed to NHS use of abiraterone, used on al-Megrahi, after the maker dropped its price.
http://www.telegraph.co.uk/health/h...sers-in-European-prostate-cancer-lottery.html
Dr Heather Payne, a consultant oncologist at University College London Hospitals NHS Foundation Trust, said: ?There are many reasons for international differences in cancer survival, but swift access to innovative treatments and the availability of best practice care are important in order to deliver the best outcomes in terms of life extension and quality of life.
She added: ?With advanced prostate cancer we are dealing with an incurable disease and every month matters for these men."
The National Institute for Health and Clinical Excellence (Nice) has been slow to recommend new prostate cancer drugs for NHS use.
Last year it said two breakthrough drugs were too expensive, including one understood to have been used in Libya to extend the life of Abdelbaset al-Megrahi, the Lockerbie bomber. It later agreed to NHS use of abiraterone, used on al-Megrahi, after the maker dropped its price.
http://www.telegraph.co.uk/health/h...sers-in-European-prostate-cancer-lottery.html